CTLA4 and multiple sclerosis: The SJL mouse EAE model using the PLP139–151 peptide is more relevant to human multiple sclerosis as it has a relapse phase.[18] Mice were treated with dNP2‐ctCTLA‐4 or CTLA‐4‐Ig on the day when disease relapse was observed (Figure 5g).